Berkshire Capital Holdings’s OptimizeRx OPRX Stock Holding History

Berkshire Capital Holdings’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	–	–	91
2022 Q1	$0	Hold	10	–	–	﹤0.01%	85
2021 Q4	$1K	Sell	10 -378,670	-100%	-$28.7M	﹤0.01%	69
2021 Q3	$32.4M	Buy	378,680 +378,670	+3,786,700%	+$23.8M	4.35%	11
2021 Q2	$1K	Buy	+10	New	+$509	﹤0.01%	78

Other funds holding OPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Berkshire Capital Holdings's OPRX Position: Q2 2022 in Review

Berkshire Capital Holdings sold out of OptimizeRx (OPRX) in Q2 2022, closing a stake of 10 shares.

Berkshire Capital Holdings first reported a position in OPRX in Q2 2021 and held it in 4 quarters. The position peaked at $32.4M in Q3 2021. 147 funds tracked by Wall St. Rank hold OPRX as of Q2 2022.

Berkshire Capital Holdings reported no remaining OptimizeRx position as of Q2 2022 after selling out during the quarter.
Berkshire Capital Holdings sold 10 OptimizeRx shares in Q2 2022.
Berkshire Capital Holdings first reported a position in OptimizeRx in Q2 2021 and held it in 4 quarters.
Berkshire Capital Holdings's OptimizeRx position peaked at $32.4M in Q3 2021.
147 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2022.

Based on Berkshire Capital Holdings's 13F filing for Q2 2022, filed 11 Aug 2022.